Conjunctivitis and COVID‐19: A meta‐analysis

Lorenzo Loffredo,Fernanda Pacella,Elena Pacella,Giulia Tiscione,Alessandra Oliva,Francesco Violi
DOI: https://doi.org/10.1002/jmv.25938
IF: 20.693
2020-05-22
Journal of Medical Virology
Abstract:<section class="article-section__content"><p>There are sparse data in literature regarding conjunctivitis incidence in COVID‐19 and its relationship with disease severity.</p><p>The objective of this metanalysis was to assess the association between conjunctivitis and the severity of COVID‐19 disease.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We performed a meta‐analysis with studies that included patients with severe vs non‐severe form of COVID‐19 infection. Severe COVID‐19 infection was defined as severe pneumonia, mortality, acute respiratory distress syndrome (ARDS), use of mechanical ventilation or Intensive Care Unit (ICU) treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Three studies, including 1167 patients, reported the incidence of conjunctivitis at admission to the hospital. The overall rate of conjunctivitis was 1.1%; it was 3% and 0.7% in severe and non‐severe COVID‐19 patients, respectively. Patients with severe COVID‐19 had an increased incidence of conjunctivitis (O.R.:3.4; 95% C.I.:1.1‐10.2; p=0.030).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Conjunctivitis is more frequent in severe COVID and may be a warning sign of poor outcomes.</p><p>This article is protected by copyright. All rights reserved.</p></section>
virology
What problem does this paper attempt to address?